% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Bielesch:309981,
author = {S. Bielesch and I. Vogel and S. Nokodian and J. Moeller and
A. Blechschmidt and V. Hecht and V. Kuentzel and K. Thiedig
and M. Schwab and O. Schilling and H. Bronger$^*$ and M.
Kiechle and V. Magdolen and T. Dreyer$^*$},
title = {{K}eratin 19 as a prognostic marker and contributing factor
of metastasis and chemoresistance in high-grade serous
ovarian cancer.},
journal = {Molecular oncology},
volume = {nn},
issn = {1574-7891},
address = {Hoboken, NJ},
publisher = {John Wiley $\&$ Sons, Inc.},
reportid = {DKFZ-2026-00407},
pages = {nn},
year = {2026},
note = {epub},
abstract = {High-grade serous ovarian cancer (HGSOC) is the most
prevalent and lethal subtype of epithelial ovarian cancer
(EOC), characterised by extensive peritoneal metastasis. The
intermediate filament keratin 19 (KRT19) has been linked to
tumour progression and chemoresistance in various cancers.
However, its role varies across tumour types and remains
unclear for HGSOC. We evaluated KRT19 protein expression in
199 HGSOC patients and correlated findings with clinical
outcomes. In vitro, we assessed the effects of KRT19 on
tumour-associated mechanisms, including proliferation,
migration, adhesion, and spheroid formation. A xenograft
mouse model was used to assess tumour burden in vivo.
Publicly available datasets enabled in silico validation.
KRT19 was significantly overexpressed in HGSOC, and high
expression was associated with reduced overall survival. In
vivo, KRT19-overexpression increased peritoneal tumour
burden. In vitro and ex vivo, KRT19 induced a hybrid
epithelial phenotype through enhanced epithelial-mesenchymal
plasticity (EMP), promoting adhesion, migration, and
spheroid integrity, thereby potentially supporting
metastatic processes. Further, KRT19 could contribute to
paclitaxel resistance. Altogether, KRT19 represents a
potential independent prognostic marker and therapeutic
target to inhibit metastatic dissemination.},
keywords = {chemoresistance (Other) / epithelial–mesenchymal
plasticity (Other) / keratin 19 (Other) / ovarian cancer
(Other)},
cin = {MU01},
ddc = {610},
cid = {I:(DE-He78)MU01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41714116},
doi = {10.1002/1878-0261.70227},
url = {https://inrepo02.dkfz.de/record/309981},
}